Authors

Latest:

Value and Market Access Considerations Often Missing From Trial Design

Having an evidence package at launch that satisfies payersâ€™ value criteria will increase the likelihood that payers will reimburse the drug at a desirable price and enable patient access to innovative treatments.

Medical Center

Meena Savur Moran, MD

Latest:

Dr. Moran on Techniques to Decrease Toxicities With Radiation in Breast Cancer

Meena Savur Moran, MD, radiation oncologist, professor, Therapeutic Radiology, director, Breast Cancer Radiotherapy Program, Yale Cancer Center, discusses some of the techniques that oncologists can use to decrease the toxicities associated with radiation therapy when treating patients with breast cancer.

Megan E. Daly, MD

Latest:

Dr. Daly on Clinical Trials With Radiation Therapy in Lung Cancer

Megan E. Daly, MD, assistant professor of radiation oncology, UC Davis Cancer Center, discusses upcoming clinical trials involving radiation therapy for the treatment of lung cancer.

Megan Garlapow, PhD

Latest:

Immunotherapy Continues to Advance in Head and Neck Cancer

An early-stage trial is examining the addition of nivolumab to a cetuximab regimen in head and neck squamous cell carcinoma.

Megan Kruse, MD, of Cleveland Clinic

Latest:

Clinical Benefits With Neratinib in HER2+ Early Breast Cancer

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.

Mehmet Asim Bilen, MD, Emory University School of Medicine

Latest:

Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC

The panel discusses the best approaches to treating patients with non-clear cell RCC.

Mehmet Sitki Copur, MD

Latest:

The Longstanding Quest for a Better Endocrine Therapy Continues High-Dose Fulvestrant: Have We Found Its Effective Dose, Combination, Setting, or Sequence?

Although several endocrine therapies are available today, the authors of this commentary contend that the quest for a better tamoxifen is ongoing.

Mehmood Hashmi, MD

Latest:

Dr. Hashmi on Immunotherapy in Prostate Cancer

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses the use of immunotherapy in the treatment of patients with prostate cancer.

Meir Rinde

Latest:

Fixed-Duration Therapy Struggles to Find Footing Across Tumor Types

Fixed-duration systemic therapies have gained some traction in hematologic malignancies, where advances in drug development and sequencing strategies have afforded investigators the opportunity to conduct trials.

Meir Wetzler, MD

Latest:

Novel Therapies for T315I-Mutant Chronic Myeloid Leukemia

Abelson tyrosine kinase (ABL1) is a nonreceptor tyrosine kinase involved in cell growth and proliferation.

Melanie B. Thomas, MD

Latest:

Dr. Thomas Discusses the Potential Utility for PF-03446962 in HCC

Melanie B. Thomas, MD, medical oncologist, associate director for clinical trials, Hollings Cancer Center, Medical University of South Carolina, discusses the potential utility for the monoclonal antibody PF-03446962 in hepatocellular carcinoma (HCC).

Melanie C. Majure, MD

Latest:

Dr. Majure on Unmet Needs for Patients With TNBC

Melanie C. Majure, MD, assistant clinical professor in the Division of Hematology/Oncology and breast oncologist, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses unmet needs for patients with triple-negative breast cancer (TNBC).

Melanie E. Royce, MD, PhD

Latest:

Dr. Royce on Progress Being Made in HER2+ Positive Breast Cancer

Melanie E. Royce, MD, PhD, co-director, Protocol Review and Monitoring System, member, Women’s Cancers Research Program, associate professor of Medicine, University of New Mexico Comprehensive Cancer Center, discusses some of the progress currently being made in the field of HER2-positive breast cancer.

Meletios A. Dimopoulos, MD

Meletios A. Dimopoulos, MD, is an a professor and chairman in the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine

Latest:

Dr Dimopoulos on BVd vs DVd in Relapsed/Refractory Multiple Myeloma With High-Risk Cytogenetic Features

Meletios A. Dimopoulos, MD, discusses the efficacy of BVd vs DVd in patients with relapsed or refractory multiple myeloma.

Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens

Latest:

“Multiple Myeloma Talk”: A Review of Data from the ASH 2020 Virtual Meeting

Meletios Dimopoulos, MD

Latest:

Dr. Dimopoulos Reflects on Ibrutinib Plus Rituximab in Waldenstrom Macroglobulinemia

Meletios Dimopoulos, MD, professor and chairman, Department of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, discusses the impact of the results from the iNNOVATE study of ibrutinib (Imbruvica) plus rituximab (Rituxan) in patients with Waldenström macroglobulinemia.

Melinda L. Irwin, PhD

Latest:

Melinda Irwin on Impact of Exercise on Survivors' Quality of Life

Melinda Liggett Irwin, PhD, MPH, associate professor of epidemiology (chronic diseases), Yale School of Public Health, co-program leader, Cancer Prevention and Control Research Program, Yale Cancer Center, discusses the impact of the LIVESTRONG at the YMCA Program on survivors' fitness, physical activity, and quality of life.

Melissa A. Wilson, MD, PhD

Latest:

Dr. Wilson on Choosing Between BRAF/MEK Therapies for Patients With Melanoma

Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses how physicians select between the 2 BRAF/MEK inhibitor combination regimens for their patients with melanoma.

Melissa Andres, BSN, RN, OCN, CBPN-C

Latest:

The Heart of Collaboration: Oncologists and Nurses Working Together

The culture of the nurse-physician relationship has changed dramatically over the past years and is one of the most important drivers of a healthy work environment